The group's principal activities are to discover, develop and acquire pharmaceutical compounds for the treatment of memory and cognitive disorders. The group identifies and acquires novel post-discovery central nervous system drug candidates. It acquires the patent rights to these candidates and advances the compounds through clinical development towards regulatory approval. The group has acquired worldwide exclusive patent rights to three main classes of therapeutic compounds designed for the treatment of alzheimer's disease, mild cognitive impairment and related diseases. These patent rights were licensed from the New York university via a sublicense from the national institutes of health and the national institute of aging. Phenserine is its main product, which is used for treating alzheimer's disease. On 15-Jan-2004, the group acquired oxis international inc.
